Reperfusion injury after critical intestinal ischemia and its correction with perfluorochemical emulsion "perftoran"

Кожура, В. Л.; Басараб, Д. А.; Timkina, M. I.; Golubev, Arkadiy Mikhailivich; Reshetnyak, Vasiliy Ivanovich; Мороз, В. В

doi:10.3748/wjg.v11.i45.7084

Cited by 17 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their study, the administration of Perftoran as a bolus over 5 min did not cause any changes in microvessel diameter or tone, defined as the ability to constrict or dilate when phenylephrine or acetycholine, respectively, were topically applied to the muscle. In another intravital microscopy study that examined the effects of PFC on intestinal ischemia/reperfusion, treatment with Perftoran reduced the observed constriction in rat mesenteric arteries during the reperfusion period by ~20% [19]. To our knowledge, the present study is the first to assess the vasoactive effects of Perftoran on cerebral vasculature.…”

Section: Discussionmentioning

confidence: 80%

Cerebral Microvascular and Systemic Effects Following Intravenous Administration of the Perfluorocarbon Emulsion Perftoran

Abutarboush

Saha

Mullah

et al. 2016

JFB

View full text Add to dashboard Cite

Oxygen-carrying perfluorocarbon (PFC) fluids have the potential to increase tissue oxygenation during hypoxic states and to reduce ischemic cell death. Regulatory approval of oxygen therapeutics was halted due to concerns over vasoconstrictive side effects. The goal of this study was to assess the potential vasoactive properties of Perftoran by measuring brain pial arteriolar diameters in a healthy rat model. Perftoran, crystalloid (saline) or colloid (Hextend) solutions were administered as four sequential 30 min intravenous (IV) infusions, thus allowing an evaluation of cumulative dose-dependent effects. There were no overall changes in diameters of small-sized (<50 μm) pial arterioles within the Perftoran group, while both saline and Hextend groups exhibited vasoconstriction. Medium-sized arterioles (50–100 μm) showed minor (~8–9%) vasoconstriction within saline and Hextend groups and only ~5% vasoconstriction within the Perftoran group. For small- and medium-sized pial arterioles, the mean percent change in vessel diameters was not different among the groups. Although there was a tendency for arterial blood pressures to increase with Perftoran, pressures were not different from the other two groups. These data show that Perftoran, when administered to healthy anesthetized rats, does not cause additional vasoconstriction in cerebral pial arterioles or increase systemic blood pressure compared with saline or Hextend.

show abstract

Section: Discussionmentioning

confidence: 80%

Cerebral Microvascular and Systemic Effects Following Intravenous Administration of the Perfluorocarbon Emulsion Perftoran

Abutarboush

Saha

Mullah

et al. 2016

JFB

View full text Add to dashboard Cite

show abstract

“…Ischemia. Systemic administration of Perftoran after ischemia promoted earlier and more complete structural regeneration during reperfusion (39).…”

mentioning

confidence: 99%

Perfluorocarbon‐Based Oxygen Carriers: Review of Products and Trials

2010

View full text Add to dashboard Cite

A viable blood substitute is still of great necessity throughout the world. Perfluorocarbon-based oxygen carriers (PFCOCs) are emulsions that take advantage of the high solubility of respiratory gases in perfluorocarbons (PFCs). Despite attractive characteristics, no PFCOC is currently approved for clinical uses. Some PFCOCs have failed due to secondary effects of the surfactants employed, like Fluosol DA, whereas others to adverse cerebrovascular effects on cardiopulmonary bypass, such as Oxygent. Further in-depth, rigorous work is needed to overcome the annotated failures and to obtain a safe PFCOC approved for human use. The aim of this study is to review in detail the most-used PFCOCs, their formulation, and preclinical and clinical trials, and to reflect upon causes of failure and strategies to overcome such failures.

show abstract

“…This drug improves microcirculation and stabilizes blood rheology [1,[4][5][6]10,13]. Detoxifying and absorbing effects of Perftoran under pathological conditions also contribute to a decrease in rat lymph toxicity after lymphotropic administration of the preparation [7].…”

Section: Resultsmentioning

confidence: 99%

“…It should be emphasized that Perftoran (plasma substitute of multiple action) has the oxygen-transport, anti-acidifying, membrane-stabilizing, and thrombolytic properties. This drug improves microcirculation and stabilizes blood rheology [1,[4][5][6]10,13]. Detoxifying and absorbing effects of Perftoran under patho-…”

mentioning

confidence: 99%

Lymphoprotective Effect of Perftoran

et al. 2010

View full text Add to dashboard Cite

Experiments on rats showed that the lymphoprotective effect of Perftoran manifests in stimulation of contractile activity of myocytes in the wall and valve cusps of lymphatic microvessels, which in turn activates the pump and capacitive functions of the lymphatic system and improves central lymph outflow. These changes contribute to an increase in the resorption and transport of cell and tissue metabolites from the interstitial space.

show abstract

Reperfusion injury after critical intestinal ischemia and its correction with perfluorochemical emulsion "perftoran"

Abstract: Systemic administration of perftoran promotes earlier and more complete structural regeneration during reperfusion in rats after partial and global critical intestinal ischemia.

Cited by 17 publications

References 15 publications

Cerebral Microvascular and Systemic Effects Following Intravenous Administration of the Perfluorocarbon Emulsion Perftoran

Cerebral Microvascular and Systemic Effects Following Intravenous Administration of the Perfluorocarbon Emulsion Perftoran

Perfluorocarbon‐Based Oxygen Carriers: Review of Products and Trials

Lymphoprotective Effect of Perftoran

Contact Info

Product

Resources

About